Pulmatrix: Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K

(marketscreener.com) Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously administered DHE. Self-administered PUR3100 showed improved...https://www.marketscreener.com/quote/stock/PULMATRIX-INC-54548233/news/Pulmatrix-Announces-Peer-Reviewed-Publication-of-Clinical-Results-for-its-Orally-Inhaled-DHE-for-A-46734293/?utm_medium=RSS&utm_content=20240515